Sanofi wants Mylan to pay up to US$11.7 billion in damages for engaging in a scheme to squelch competition to its EpiPen allergy treatment, which became the center of a firestorm over drug price increases.
The French drugmaker detailed its damages claim on Friday, August 9, as it urged a federal judge in Kansas City, Kansas, to allow it to proceed with a lawsuit alleging Mylan took actions to crush the competitive threat posed by Sanofi’s newer product, Auvi-Q.
In the suit filed in Trenton, New Jersey, Sanofi claimed Mylan caused it to lose hundreds of millions of dollars in sales by erecting barriers to US consumers’ access to and use of a rival product, Auvi-Q.
In particular, Sanofi claimed Mylan offered rebates to insurers, pharmaceutical benefit managers, and state Medicaid agencies conditioned on Auvi-Q not being an epinephrine auto-injector device they would reimburse for use by consumers.
Full Content: Reuters